《中国晚期非小细胞肺癌分子靶向治疗专家共识（2013年版）》 - Suppr | 超能文献

文献检索
文档翻译
深度研究
学术资讯

Zotero 插件

邀请有礼
套餐&价格
历史记录

应用&插件

Zotero 插件浏览器插件 Mac 客户端 Windows 客户端微信小程序

定价

高级版会员购买积分包购买API积分包

服务

文献检索文档翻译深度研究 API 文档 MCP 服务

关于我们

关于 Suppr 公司介绍联系我们用户协议隐私条款

关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究

粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1

Chinese expert consensus on molecularly targeted therapy for advanced non-small cell lung cancer (2013 edition).《中国晚期非小细胞肺癌分子靶向治疗专家共识（2013年版）》

J Thorac Dis. 2014 Oct;6(10):1489-98. doi: 10.3978/j.issn.2072-1439.2014.09.20.

2

[Chinese expert consensus on immunotherapy for advanced non-small lung cancer with oncogenic driver mutations (2022 edition)].《中国晚期非小细胞肺癌驱动基因变异免疫治疗专家共识（2022年版）》

Zhonghua Zhong Liu Za Zhi. 2022 Oct 23;44(10):1047-1065. doi: 10.3760/cma.j.cn112152-20220614-00416.

3

[Chinese expert consensus on immunotherapy for advanced non-small lung cancer with oncogenic driver mutations (2023 edition)].《中国晚期非小细胞肺癌驱动基因变异免疫治疗专家共识（2023年版）》

Zhonghua Zhong Liu Za Zhi. 2023 Sep 23;45(9):717-740. doi: 10.3760/cma.j.cn112152-20230420-00179.

4

[Chinese expert consensus on Anlotinib Hydrochloride for advanced lung cancer (2020 edition)].《盐酸安罗替尼治疗晚期肺癌中国专家共识（2020年版）》

Zhonghua Zhong Liu Za Zhi. 2020 Oct 23;42(10):807-816. doi: 10.3760/cma.j.cn112152-20200721-00669.

5

[Chinese expert consensus on antiangiogenic drugs for advanced non-small cell lung cancer (2020 Edition)].《中国晚期非小细胞肺癌抗血管生成药物专家共识（2020年版）》

Zhonghua Zhong Liu Za Zhi. 2020 Dec 23;42(12):1063-1077. doi: 10.3760/cma.j.cn112152-20200918-00836.

6

[Chinese expert consensus on the diagnosis and treatment of advanced RET fusion-positive non-small cell lung cancer (2023 edition)].《中国晚期RET融合阳性非小细胞肺癌诊疗专家共识（2023年版）》

Zhonghua Zhong Liu Za Zhi. 2023 Dec 23;45(12):991-1002. doi: 10.3760/cma.j.cn112152-20230711-00290.

7

[Chinese expert consensus on iruplinalkib for the treatment of locally advanced or metastatic ALK-positive non-small cell lung cancer (2024 edition)].《艾乐替尼治疗局部晚期或转移性ALK阳性非小细胞肺癌中国专家共识（2024年版）》

Zhonghua Zhong Liu Za Zhi. 2024 Mar 23;46(3):189-205. doi: 10.3760/cma.j.cn112152-20230901-00110.

8

[Chinese expert consensus on evaluation and treatment of advanced non-small cell lung cancer with negative driver genes after first-line immunotherapy resistance (2024 edition)].《一线免疫治疗耐药后驱动基因阴性晚期非小细胞肺癌评估与治疗中国专家共识（2024年版）》

Zhonghua Yi Xue Za Zhi. 2024 Feb 6;104(6):411-426. doi: 10.3760/cma.j.cn112137-20230927-00589.

9

[Chinese Expert Consensus on Antiangiogenic Drugs for Advanced Non-small Cell Lung Cancer (2019 Edition)].《中国晚期非小细胞肺癌抗血管生成药物治疗专家共识（2019年版）》

Zhongguo Fei Ai Za Zhi. 2019 Jul 20;22(7):401-412. doi: 10.3779/j.issn.1009-3419.2019.07.01.

10

[Chinese expert consensus on stereotactic body radiation therapy for early stage non-small cell lung cancer (2019 Edition)].《中国早期非小细胞肺癌立体定向体部放射治疗专家共识（2019版）》

Zhonghua Zhong Liu Za Zhi. 2020 Jul 23;42(7):522-530. doi: 10.3760/cma.j.cn112152-20200116-00039.

引用本文的文献

1

Characteristics and risk factors for advanced lung cancer with pulmonary embolism: A cross-sectional, case-control study.特征与具有肺栓塞的晚期肺癌的风险因素：一项横断面、病例对照研究。

Clin Respir J. 2023 Oct;17(10):1048-1057. doi: 10.1111/crj.13692. Epub 2023 Sep 7.

本文引用的文献

1

Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors.表皮生长因子受体酪氨酸激酶抑制剂获得性耐药的晚期非小细胞肺癌中厄洛替尼化疗或单纯化疗。

Oncologist. 2013;18(11):1214-20. doi: 10.1634/theoncologist.2013-0168. Epub 2013 Sep 26.

2

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.厄洛替尼对比吉非替尼用于经治的晚期非小细胞肺癌（ICOGEN）：一项随机、双盲、III 期非劣效性试验

Lancet Oncol. 2013 Sep;14(10):953-61. doi: 10.1016/S1470-2045(13)70355-3. Epub 2013 Aug 13.

3

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.厄洛替尼对比多西他赛作为晚期非小细胞肺癌且 EGFR 野生型患者二线治疗选择（TAILOR）：一项随机对照试验。

Lancet Oncol. 2013 Sep;14(10):981-8. doi: 10.1016/S1470-2045(13)70310-3. Epub 2013 Jul 22.

4

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.III 期研究阿法替尼或顺铂加培美曲塞治疗 EGFR 突变的转移性肺腺癌患者。

J Clin Oncol. 2013 Sep 20;31(27):3327-34. doi: 10.1200/JCO.2012.44.2806. Epub 2013 Jul 1.

5

Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.晚期非小细胞肺癌患者化疗联合厄洛替尼治疗（FASTACT-2）：一项随机、双盲试验。

Lancet Oncol. 2013 Jul;14(8):777-86. doi: 10.1016/S1470-2045(13)70254-7. Epub 2013 Jun 17.

6

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.克唑替尼与化疗用于治疗晚期 ALK 阳性肺癌。

N Engl J Med. 2013 Jun 20;368(25):2385-94. doi: 10.1056/NEJMoa1214886. Epub 2013 Jun 1.

7

Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer.表皮生长因子受体酪氨酸激酶抑制剂失败的临床模式及晚期非小细胞肺癌的后续管理。

Lung Cancer. 2013 Jan;79(1):33-9. doi: 10.1016/j.lungcan.2012.09.016. Epub 2012 Oct 15.

8

First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial.一线厄洛替尼治疗不适合化疗的晚期非小细胞肺癌患者（TOPICAL）：一项双盲、安慰剂对照、3 期临床试验。

Lancet Oncol. 2012 Nov;13(11):1161-70. doi: 10.1016/S1470-2045(12)70412-6. Epub 2012 Oct 16.

9

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.转移性非小细胞肺癌（NSCLC）：ESMO诊断、治疗及随访临床实践指南

Ann Oncol. 2012 Oct;23 Suppl 7:vii56-64. doi: 10.1093/annonc/mds226.

10

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.ALK 阳性非小细胞肺癌患者中克唑替尼的活性和安全性：来自一项 I 期研究的更新结果。

Lancet Oncol. 2012 Oct;13(10):1011-9. doi: 10.1016/S1470-2045(12)70344-3. Epub 2012 Sep 4.

Chinese expert consensus on molecularly targeted therapy for advanced non-small cell lung cancer (2013 edition).

作者信息

Wu Guoming, Zhou Caicun, Bai Chunxue, Qian Guisheng

机构信息

1 Xinqiao Hospital of the Third Military Medical University, Chongqing 400037, China ; 2 Pulmonary Hospital of Tongji University, Shanghai 200433, China ; 3 Zhongshan Hospital of Fudan University, Shanghai 200032, China.

出版信息

J Thorac Dis. 2014 Oct;6(10):1489-98. doi: 10.3978/j.issn.2072-1439.2014.09.20.

DOI:10.3978/j.issn.2072-1439.2014.09.20

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4215143/

Abstract

摘要